Inspire Vet Files S-1 for 46.4M Share Resale; No New Capital Raised

TL;DR

**IVPR's S-1 is a massive overhang of shares hitting the market, signaling potential dilution and a bearish outlook for the stock price.**

AI Summary

Inspire Veterinary Partners, Inc. (IVPR) is filing an S-1 to register 46,419,092 shares of Class A common stock for resale by existing Selling Stockholders, not to raise new capital for the company. These shares include 26,194,092 shares from the conversion of Series B preferred stock in a July 28, 2025 private placement, 18,975,000 shares from warrant exercises at $1.00 per share, and 1,250,000 shares from the conversion of $1,250,000 in promissory notes issued to Target Capital, LLC on June 10 and June 30, 2025. The company, which operates fourteen veterinary hospitals across nine states, completed its IPO on August 31, 2023, and its stock traded at $0.993 per share on October 2, 2025. IVPR will not receive any proceeds from this offering, but will bear all registration expenses. The company is an 'emerging growth company' and 'smaller reporting company' and faces significant risks, including a limited operating history, unprofitability, and a Nasdaq listing deficiency notice.

Why It Matters

This S-1 filing is crucial for investors as it signals a significant potential increase in the public float of IVPR's Class A common stock by 46,419,092 shares, representing a substantial dilution risk given only 3,609,285 shares were outstanding prior to this offering. While the company won't receive direct proceeds, the influx of shares from selling stockholders could depress the market price, impacting existing shareholders. For employees and customers, the filing highlights the company's growth strategy through acquisitions of veterinary hospitals, but also underscores its unprofitability and 'emerging growth company' status, suggesting ongoing financial challenges in a competitive animal health industry.

Risk Assessment

Risk Level: high — The risk level is high due to the registration of 46,419,092 shares for resale by Selling Stockholders, which is over 12 times the 3,609,285 shares outstanding prior to this offering, creating significant potential for dilution. Furthermore, the company explicitly states it has a 'limited operating history, are not profitable and may never become profitable,' and has received a 'listing deficiency notice from Nasdaq regarding our Class A Common Stock,' indicating severe operational and financial instability.

Analyst Insight

Investors should exercise extreme caution and consider avoiding IVPR stock given the substantial dilution risk from the 46,419,092 shares being registered for resale. The company's unprofitability, limited operating history, and Nasdaq listing deficiency are major red flags that suggest significant downside potential.

Key Numbers

• 46,419,092 shares — Class A Common Stock offered by Selling Stockholders (Represents a significant potential increase in public float and dilution.)
• 3,609,285 shares — Class A Common Stock outstanding immediately prior to this offering (The offering shares are over 12 times this amount, indicating massive dilution.)
• $0.993 — Last reported sale price of Class A Common Stock (Price on Nasdaq Capital Market on October 2, 2025, indicating low stock value.)
• $1.00 — Exercise price of warrants (For 18,975,000 shares issued to Private Placement investors.)
• $1,250,000 — Aggregate principal amount of promissory notes (Issued to Target Capital, LLC, convertible into 1,250,000 shares.)
• 14 — Number of veterinary hospitals (Currently owned and operated by Inspire Veterinary Partners, Inc. across nine states.)
• August 31, 2023 — Date of initial public offering (Marks the beginning of the company's public operating history.)
• July 28, 2025 — Date of securities purchase agreement (For the Private Placement of Series B convertible preferred stock.)
• October 2, 2025 — Date for outstanding share count (Reference date for 3,609,285 shares of Common Stock outstanding.)
• 98.0% — Voting power controlled by non-independent directors, officers, and affiliates (Indicates concentrated control despite a majority independent board.)

Key Players & Entities

• INSPIRE VETERINARY PARTNERS, INC. (company) — Registrant and veterinary hospital operator
• Target Capital, LLC (company) — Recipient of $1,250,000 in promissory notes convertible into IVPR shares
• Nasdaq Capital Market (regulator) — Listing exchange for IVPR, which issued a deficiency notice
• U.S. Securities and Exchange Commission (regulator) — Regulatory body for S-1 filing
• Sean Klein (person) — Contact person for copies of the S-1 filing
• Kimball Carr (person) — Chair, President and Chief Executive Officer of IVPR
• Spartan Capital Securities, LLC (company) — Underwriter in IVPR's initial public offering and February 2024 public offering
• Tumim Stone Capital LLC (company) — Party to a Purchase Agreement dated November 30, 2023
• Dragon Dynamic Catalytic Bridge SAC Fund (company) — Holder of warrants convertible into IVPR shares
• 622 Capital LLC (company) — Holder of warrants convertible into IVPR shares

FAQ

Risk Factors

• Significant Dilution from Resale of Shares [high — financial]: The offering registers 46,419,092 shares for resale, which is over 12 times the 3,609,285 shares outstanding as of October 2, 2025. This massive increase in public float will significantly dilute existing shareholders' ownership percentage.
• Low Stock Price and Nasdaq Listing Deficiency [high — financial]: The Class A common stock last traded at $0.993 per share on October 2, 2025, indicating a low valuation. Furthermore, the company has received a Nasdaq listing deficiency notice, posing a risk to its continued exchange listing.
• Unprofitability and Limited Operating History [high — financial]: As an 'emerging growth company' and 'smaller reporting company,' IVPR faces significant risks due to its limited operating history and current unprofitability. This lack of a track record makes future performance highly uncertain.
• Concentrated Control by Insiders [medium — financial]: Non-independent directors, officers, and affiliates control approximately 98.0% of the voting power. This concentrated control could lead to decisions that benefit insiders over minority shareholders.
• Warrant and Option Overhang [high — financial]: A substantial number of shares are issuable upon exercise of warrants and stock options, many with exercise prices significantly below the current trading price. For example, 18,975,000 shares are issuable from warrants at $1.00, and other warrants have exercise prices as high as $11,000. This overhang could lead to future dilution and downward pressure on the stock price.

Industry Context

The veterinary services industry is characterized by a mix of independent practices and consolidating groups. While demand for pet care remains strong, driven by increasing pet ownership and humanization of pets, the market is competitive. Companies like Inspire Veterinary Partners operate in a fragmented landscape, facing competition from both small local clinics and larger corporate consolidators.

Regulatory Implications

As a publicly traded company, IVPR is subject to SEC regulations and Nasdaq listing rules. The company's receipt of a Nasdaq listing deficiency notice highlights potential compliance issues that could impact its ability to remain listed, affecting liquidity and investor confidence.

What Investors Should Do

1. Assess dilution impact
2. Evaluate profitability and cash flow
3. Monitor Nasdaq listing status
4. Consider insider control

Key Dates

• 2025-07-28: Series B convertible preferred stock private placement — Resulted in the conversion of 26,194,092 shares of Series B preferred stock into Class A common stock, which are now being registered for resale.
• 2025-06-10: Promissory notes issued to Target Capital, LLC — These notes, totaling $1,250,000, are convertible into 1,250,000 shares of Class A common stock, which are part of the resale registration.
• 2025-06-30: Promissory notes issued to Target Capital, LLC — Additional notes issued to Target Capital, LLC, contributing to the $1,250,000 aggregate principal amount convertible into Class A common stock.
• 2023-08-31: Initial Public Offering (IPO) — Marked the company's entry into the public markets and established its initial trading history.
• 2025-10-02: Class A Common Stock outstanding count reference date — Established the baseline of 3,609,285 shares outstanding immediately prior to this resale offering.
• 2025-10-02: Last reported sale price of Class A Common Stock — Indicates the current market valuation of the company's stock at $0.993 per share.

Glossary

Selling Stockholders

Existing shareholders who are offering to sell their shares to the public, rather than the company selling new shares. (This offering involves shares being sold by existing holders, meaning the company will not receive any proceeds, but will incur registration expenses.)

Emerging Growth Company

A company that has total annual gross revenues of less than $1.235 billion during its most recently completed fiscal year. These companies are allowed certain exemptions from reporting requirements. (IVPR's status as an EGC means it faces fewer regulatory burdens but also signals a potentially less mature business.)

Smaller Reporting Company

A non-accelerated filer that is either an "emerging growth company" or has a public float of less than $250 million. They have reduced disclosure requirements. (Similar to EGC status, this indicates a smaller, less complex company with potentially less robust financial reporting.)

Class A Common Stock

The class of common stock being registered for resale in this offering. (This is the primary equity security of the company available for public trading.)

Warrants

Financial instruments that give the holder the right, but not the obligation, to purchase a company's stock at a specified price (exercise price) before a certain expiration date. (A significant number of shares (18,975,000) are being registered for resale due to warrant exercises at $1.00 per share, indicating potential future dilution.)

Promissory Notes

Written promises to pay a specific sum of money to a specific person or entity on demand or at a specified future date. (Promissory notes issued to Target Capital, LLC are convertible into 1,250,000 shares of common stock, adding to the shares available for resale.)

Private Placement

A sale of securities directly to a small group of institutional or sophisticated investors, rather than through a public offering. (The conversion of Series B preferred stock from a private placement on July 28, 2025, is a major source of the shares being registered for resale.)

Year-Over-Year Comparison

This S-1 filing focuses on the resale of a substantial number of shares by existing stockholders, rather than a primary offering to raise capital. Key metrics such as revenue, net income, and margins are not provided in this context, making a direct year-over-year comparison of financial performance impossible. The primary focus is on the significant potential dilution and the risks associated with the company's current financial state and Nasdaq listing status.

Key Financial Figures

• $0.0001 — 092 shares of our Class A common stock, $0.0001 par value per share, (the "Common Stock
• $1.00 — se of warrants (at an exercise price of $1.00 per share), issued to investors in the
• $1,250,000 — d, in the aggregate principal amount of $1,250,000 issued to Target Capital, LLC ("Target"
• $0.993 — Capital Market on October 2, 2025, was $0.993 per share. We are registering the shar
• $6,000 — to the Company at an exercise price of $6,000 per share and have an expiration date o
• $11,000 — public offering at an exercise price of $11,000 per share and have an expiration date o
• $10,000 — 622 Capital LLC at an exercise price of $10,000 per share and have an expiration date o
• $233.75 — public offering at an exercise price of $233.75 per share and have an expiration date o
• $17.00 — at a weighted average exercise price of $17.00 per share. The stock options were grant
• $1.71 — stock options, at an exercise price of $1.71 per share. The stock options were grant
• $1.62 — stock options, at an exercise price of $1.62 per share. The stock options were grant
• $1.46 — stock options, at an exercise price of $1.46 per share. The stock options were grant
• $1.83 — ional investor, at an exercise price of $1.83 per share and have an expiration date o
• $2.29 — onal investors, at an exercise price of $2.29 per share and have an expiration date o
• $14,264,261 — elve months ended December 31, 2024 was $14,264,261 and for the year ended December 31, 202

Filing Documents

• ea0260186-s1_inspire.htm (S-1) — 3099KB
• ea026018601ex5-1_inspire.htm (EX-5.1) — 12KB
• ea026018601ex23-1_inspire.htm (EX-23.1) — 2KB
• ea026018601ex-fee_inspire.htm (EX-FILING FEES) — 19KB
• image_001.jpg (GRAPHIC) — 4KB
• image_002.jpg (GRAPHIC) — 24KB
• image_003.jpg (GRAPHIC) — 27KB
• ex5-1_001.jpg (GRAPHIC) — 11KB
• 0001213900-25-096235.txt ( ) — 14163KB
• ivp-20250630.xsd (EX-101.SCH) — 114KB
• ivp-20250630_cal.xml (EX-101.CAL) — 88KB
• ivp-20250630_def.xml (EX-101.DEF) — 614KB
• ivp-20250630_lab.xml (EX-101.LAB) — 972KB
• ivp-20250630_pre.xml (EX-101.PRE) — 651KB
• ea0260186-s1_inspire_htm.xml (XML) — 1880KB
• ea026018601ex-fee_inspire_htm.xml (XML) — 8KB

Use of Proceeds

Use of Proceeds 22

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 2 3 Our

Business

Business 65 Management and Board of Directors 70 Executive and Director Compensation 75

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management 80 Certain Relationships and Related Party Transactions 83

Description of Capital Stock

Description of Capital Stock 84 Private Placement of Series B Preferred Stock 89 Selling Stockholders 92 Plan of Distribution 95 Legal Matters 97 Experts 97 Where You Can Find More Information 97 Index to Financial Statement F-1 You should rely only on the information contained in this prospectus. Neither we, nor the Selling Stockholders have authorized anyone to provide information different from that contained in this prospectus. The Selling Stockholders are offering to sell, and seeking offers to buy, shares of Common Stock only in jurisdictions where offers and sales are permitted. The information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of our Common Stock. i PROSPECTUS SUMMARY Inspire Veterinary owns and operates veterinary hospitals throughout the United States. The Company specializes in small animal general practice hospitals which serve all manner of companion pets, emphasizing canine and feline breeds and including equine care. As the Company expands, it expects to acquire additional veterinary hospitals, including general practice, mixed animal facilities, and critical and emergency care. The Company completed its initial public offering on August 31, 2023 and its shares of Class A common stock are traded on The Nasdaq Capital Market under the symbol "IVP." As of the date of this prospectus, the Company currently has fourteen veterinary hospitals located in nine states. Inspire Veterinary has expanded and plans to further expand through acquisitions of existing hospitals which have the financial track record, marketplace advantages and future growth potential. Because the Company leverages a leadership and support structure which is distributed throughout the United States, acquisitions are not centralized to one geographic area. Services provided at the Company's hospitals include preventive care for compan

Use of proceeds

Use of proceeds We will not receive any proceeds from the sale of shares of our Common Stock by the Selling Stockholders

Risk factors

Risk factors Investing in our securities involves a high degree of risk. See "Risk Factors" beginning on page 6 and the other information included in this prospectus for a discussion of factors you should consider carefully before deciding to invest in our securities. Nasdaq symbol for our Class A common stock "IVP" The number of shares of our Common Stock that will be outstanding immediately after this offering is based on 3,609,285 shares of Common Stock outstanding as of October 2, 2025 and excludes an aggregate of 3,321,353 shares of Common Stock issuable upon the exercise of stock options and warrants as follows: 20 shares of Common Stock issued to our Chair, President and Chief Executive Officer Kimball Carr in connection with his personal guaranty of certain loans to the Company at an exercise price of $6,000 per share and have an expiration date of January 1, 2028; 32 shares of Common Stock that are issuable upon exercise of warrants issued in connection with the initial public offering and held by Spartan Capital Securities, LLC, the underwriter in our initial public offering at an exercise price of $11,000 per share and have an expiration date of August 29, 2030; 332 shares of Common Stock that are issuable upon exercise of the warrants held by Target Capital 1, LLC, Dragon Dynamic Catalytic Bridge SAC Fund and 622 Capital LLC at an exercise price of $10,000 per share and have an expiration date of June 30, 2028; 753 shares of Common Stock that are issuable upon exercise of warrants issued in connection with the public offering in February 2024 and held by Spartan Capital Securities, LLC, the underwriter in our public offering at an exercise price of $233.75 per share and have an expiration date of August 16, 2028; 9,459 shares of Common Stock that are issuable upon exercise of outstanding stock options, of which 9,459 have vested and are exercisable as of October 22, 2024, at a weighted average exercise price of $17.00 per share. The stoc

View Full Filing

View this S-1 filing on SEC EDGAR